



Page 1 of 2

[X] Original [] Supplemental

Atty.Docket: REISNER = 5

Combined Declaration for Patent Application and Power of Attorney

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name; and that I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled HUMAN MONOCLONAL ANTIBODIES TO THE HEPATITIS B SURFACE ANTIGEN

the specification of which (check one)

	[] is attached hereto;	- 25 II S C 8116 on	
	[] was filed in the United States under	7 55 U.S.C. 8121 VA	
	T10031 #		_
	ryy (will be 'Sled in the II S under	35 U.S.C. §371 by entry into the U.S. national st	age of
	an international (PCT) application,	PCT/IL9//00184 ; illed 10 Jule 1997	,
	an michigania (1 0 1) -pp	*; national stage application received	•
	entry requested on		
	USSN*; §371/§10		
and was am	nended on 25 June 1998	(if applicable).	
· and was am	(include dates of amendments under FCT.	Art. 19 and 34 H.PCD	
	(Unclude dates of amendments with 1901		

I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above; and I acknowledge the duty to disclose to the Patent and Trademark Office (PTO) all information known by me to be material to nateriability as defined in 37 C. F. P. 8.1.86 patentability as defined in 37 C.F.R. § 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. §§ 119, 365 of any prior foreign application(s) for patent or inventor's certificate, or prior PCT application(s) designating a country other than the U.S., listed below with the "Yes" box checked and have also identified below any such application having a filing date before that of the application on which priority

118625 (Number)	(Country)	25 June 1998 (Day Month Year Filed)	DO Yes []	[] 00 []
(Number)	Ø (Country)	(Day Month Year Filed)	YES	NO

I hereby claim the benefit under 35 U.S.C. § 120 of any prior U.S. non-provisional Application(s) or prior PCT Application(s) designating the U.S. listed below, or under § 119(e) of any prior U.S. provisional applications listed below, and, insofar as the subject matter of each of the claims of this application is not disclosed in such U.S. or PCT application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose to the PTO all information as defined in 37 C.F.R. §1.56(a) which occurred between the filing date of the prior application and the national filing date of this application:

	· · · · · · · · · · · · · · · · · · ·	
(Application Serial No.)	(Day Month Year Filed)	(Status: patented, pending, abandoned)
(Application Serial No.)	(Day Month Year Filed)	(Status: patented, pending, abandoned)
(Application Serial No.)	(Day Month Year Filed)	(Status: patented, pending, abandoned)

I hereby appoint the following attorneys, with full power of substitution, association, and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

SHERIDAN NETHARK, REG. NO. 20,520 - ROGER L. BRONDY, REG. NO. 25,618 - ANNE M. KURNEAU, REG. NO. 25,884 NORMAN J. LATKER, REG. NO. 19,963 - IVER P. COOPER, REG. NO. 28,005 - ALLEN C. YUN, REG. NO. 37,970 MICK S. BROFFER, REG. NO. 33,478 Patent Agent

ADDRESS ALL CORRESPONDENCE TO BROWDY AND NEIMARK, P.L.L.C. 419 Seventh Street, N.W. Washington, D.C. 20004	DIRECT ALL TELEPHONE CALLS TO: BROWDY AND NEIMARK (202) 628-5197

The undersigned hereby authorizes the U.S. Attorneys or Agents named herein to accept and follow instructions from XTL BIOPHARMACEUTICALS LIMITED as to any action to be taken in the U.S. Attorneys or Agents and the undersigned. In the event of a change of the persons from whom instructions may be taken, the U.S. Attorneys or Agents named herein will be so notified by the undersigned.

1-100

æ





TO

Page 2 of 2	Any.Docket: REISNER=5	
Title: U.S. Application filed PCT Application filed	, Serial No, Serial NoPCT/IL97/00184	

I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. §1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

			- Cativer
FULL NAME OF FIRST INVENTOR	INVENTOR'S SIG	NATURE D	ATE / /98
Yair REISNER	y, King	24 L	7 b /// / 8_
RESIDENCE	· ()	CITIZENSHIP	/ /
Old Jaffa, Israel	V	Israel	
POST OFFICE ADDRESS Mazal Kashat 4, 68037 Old Jaffa, Isra	ISX	M	
FULL NAME OF SECOND JOINT INVENTOR	INVENTOR'S SI	NATURE	DATE
Shlomo DAGAN	1 St	7 /1	100/6098
		CITIZENSHIP	
RESIDENCE Rehovot, Israel		Israel	
POST OFFICE ADDRESS Bustenai 12, 76289 <u>Rehovot</u> , Israel	TJX		
FULL NAME OF THIRD JOINT INVENTOR	INVENTOR'S SIG	PNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS		<u> </u>	
	1	OKATHE P	DATE
FULL NAME OF FOURTH JOINT INVENTOR	INVENTOR'S SIC		
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF FIFTH JOINT INVENTOR	INVENTOR'S SI	GNATURE	DATE
RESIDENCE		CITIZENSHIP	X
POST OFFICE ADDRESS		<u> </u>	
PULL NAME OF SIXTH JOINT INVENTOR	INVENTOR'S SI	GNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS			
FULL NAME OF SEVENTH JOINT INVENTOR	INVENTOR'S SI	GNATURE	DATE
RESIDENCE		CITIZENSHIP	
POST OFFICE ADDRESS		 	

totally diffe, american		: :
	•	11
1		į
i	=	11
1111111	=	
The state of	=	ž
Thursday.	:	9
ando		:
Ξ		
1	:	Ē
ř		-
į.	=	Ē
ž	=	-
	=	=
than nath Hant and the	=	

	Applicant or Patentee: Yair REISNER et al. Applin. or Patent No.:			
	FOR: MUMAN MONOCLONAL ANTIBODIES TO THE HEPATITIS B SURFACE ANTIGEN			
	VERIFIED STATEMENT (DECLARATION) CLAINING SMALL BUSINESS ENTITY STATUS (37 CFR 1.9(f) and 1.27(c)) - SMALL BUSINESS CONCERN			
	I hereby declare that I am [] the owner of the small business concern identified below: [XX] an official of the small business concern empowered to act on behalf of the concern identified below:			
	NAME OF SMALL BUSINESS CONCERN YEDA RESEARCH AND DEVELOPMENT CO. LTO. ADDRESS OF SMALL BUSINESS CONCERN P.O. Box 95, Rehovot 76100, Israel			
II IIII	I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 12 CFR 121.12, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced feas to the United States Patent and Trademark Office, in that the number of employees of the concern, including those of its affiliates, does not exceed 50 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.			
1 hereby declare that rights under contract or law have been conveyed to and remain with the small busines identified above with regard to the invention entitled <u>HUMAN MONOCLONAL ANTIBODIES TO THE HEPATITIS B SURFACE</u> by inventors <u>Yair REISNER and Shlomo DAGAN</u> described in:				
± [] ±	[] the specification filed herewith with title listed as above. [XX] application no			
UH HH H. H (p.	If the rights held by the above identified small business concern are not exclusive, each individual, concern organization having rights in the invention is listed below and no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e).			
	*Note: Separate verified statements are required from each named person, concern or organization having right to the invention averring to their status as small entities (37 CFR 1.27).			
	NAME XTL BIOPHARMACEUTICALS LIMITED			
	ADDRESS Kiryat Wejzmann, P.O. Box 370, Rehovot 76100, Israel [] INDIVIDUAL DXX) SMALL BUSINESS CONCERN [] HONPROFIT ORGANIZATION			
	NAMEADDRESS			
	[] INDIVIDUAL [] SMALL BUSINESS CONCERN [] NONPROFIT ORGANIZATION			
	I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of childrent to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or a maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))			
	I hereby declare that all statements made herein of my own knowledge are true and that all statements made on informati and belief are believed to be true; and further that these statements were made with the knowledge that willful fall statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of fittle 18 of t United States Code, and that such willful false statements may Jeopardize the validity of the application, any paraliculing thereon, or any patent to which this verified atatement is directed.			
	HAME OF PERSON SIGNING PAULINA BEN-AMI TITLE OF PERSON SIGNING OTHER THAN OWNER UICE PRESIDENT ADDRESS OF PERSON SIGNING YEAR Research and Development Co. (H. P.O.B 95 Report For			





Applicant or Patentee: Yair REISNER et al. Appln. or Patent No.:	Attorney's Docket No.: <u>REISNER=5</u> Filed or Issued:
FOR: HUMAN MONOCLONAL ANTIBODIES TO THE HEPATITIS B SURFACE ANTIG	EN
VERIFIED STATEMENT (DECLARATION) GLAIMING (37 GFR 1.9(f) and 1.27(G)) - SM	
I hereby declare that I BM [] the owner of the small business concern identified below: (XX) an official of the small business concern empowered to act o	on behalf of the concern identified below:
NAME OF SMALL BUSINESS CONCERN XTL BIOPHARMACEUTICALS LIMITED ADDRESS OF SMALL BUSINESS CONCERN KITVAT VEIZMANN, P.O. Box 370.	Rehovot 76100, Israel
I hereby declare that the above identified small business concern CFR 121.12, and reproduced in 37 CFR 1.9(d), for purposes of Trademark Office, in that the number of employees of the concern, persons. For purposes of this statement, (1) the number of employer previous fiscal year of the concern of the persons employed on a fithe pay periods of the fiscal year, and (2) concerns are affiliatione concern controls or has the power to control the other, control both.	f paying reduced fees to the United States Patent and including those of its affiliates, does not exceed 500 yees of the business concern is the average over the full-time, part-time or temporary basis during each of lates of each other when either, directly or indirectly,
I hereby declare that rights under contract or law have been contracted above with regard to the invention entitled HUMAN MONO by inventors Yair REISNER and Shlomo DAGAN described in:	onveyed to and remain with the small business concern OCLONAL ANTIBODIES TO THE HEPATITIS B SURFACE ANTIGEN
[] the specification filed herewith with title listed as at [XX] application no	
If the rights held by the above-identified small business or organization having rights in the invention is listed below and then the inventor, who would not qualify as an independent in invention, or by any concern which would not qualify as a small organization under 37 CFR 1.9(e).	no rights to the invention are neto by any person, other neventor under 37 CFR 1.9(c) if that person made the
*Note: Separate verified statements are required from to the invention overring to their status as small entities.	each nemed person, concern or organization having rights ties (37 CFR 1.27).
NAME YEDA RESEARCH AND DEVELOPMENT CO. LTD.	
ADDRESS P.O, Box 95, Rehovot 76100, Israel [] INDIVIDUAL [XX] SMALL BUSINESS CONCERN [] NONI	PROFIT ORGANIZATION
ADDRESS ADDRESS	PROFIT ORGANIZATION
I acknowledge the duty to file, in this application or patent, nentitlement to small entity status prior to paying, or at the maintenance fee due after the date on which status as a small ent	otification of any change in status resulting in loss of time of paying, the earliest of the lasue fee or any ity is no longer appropriate. (37 CFR 1.28(b))
I hereby declare that all statements made herein of my own knowled and belief are believed to be true; and further that these statements and the like so made are punishable by fine or improved that such willful false atatements may Je issuing thereon, or any patent to which this verified statement is	ents were made with the knowledge that with the interest in the interest in 1001 of Title 18 of the application, any patent
NAME OF PERSON SIGNING MITH LOTAN TITLE OF PERSON SIGNING OTHER THAN OWNER PATENT ATT ADDRESS OF PERSON SIGNING XTL BIOPHARMACEUTIC REPOYDE TO TO TENTE	OR SET LIMITED, KINYAT WEIZMANN, P.O. B.370 DATE December 10, 1998